A risk reduction approach for schizophrenia: The early psychosis intervention programme

Annals of the Academy of Medicine Singapore

Volumn 33, Issue 5, 2004, Pages 630-635

  Chong, Siow Ann ^a   Lee, C ^a   Bird, L ^a   Verma, S ^a  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

Author keywords

Duration of untreated psychosis; Primary healthcare providers; Prodrome; Public education; Stigmatisation; Traditional healers

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL TRIAL; COGNITIVE THERAPY; COUNSELING; DRUG EFFICACY; DRUG SAFETY; EDUCATION; FAMILY THERAPY; HEALTH CARE COST; HUMAN; INCIDENCE; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; PRIMARY HEALTH CARE; PROGNOSIS; PSYCHOSIS; PSYCHOTHERAPY; REHABILITATION; REVIEW; RISK REDUCTION; SCHIZOPHRENIA; SUPPORT GROUP; WEIGHT GAIN;

EID: 10344262558     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Murray CJL, Lopez AD, editors. The Global Burden of Disease. Boston: Harvard University Press, 1996.
2. Rice DP, Miller LS. The economics burden of schizophrenia: conceptual and methodology issues and cost estimates. In: Moscarelli M, Rupp A, Sartorius N, editors. Handbook of Mental Health Economics and Health Policy Vol 1. Schizophrenia. New York: Wiley, 1996:321-34.
3. Warner R, de Girolamo G. Epidemiology of Mental Disorders and Psychosocial Problems: Schizophrenia. Geneva: World Health Organization, 1995.
4. Hafner H, Maurer K, Loffler W, Fatkenheuer B, an der Heiden W, Riecher-Rossler A, et al. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry 1994;164(Suppl 23):29-38.
5. Olin SS, Mednick SA. Risk factors for psychosis: identifying vulnerable population premorbidly. Schizophr Bull 1996;22:223-40.
6. Jablensky A. Schizophrenia epidemiology. Curr Opin Psychiatry 1999;12:19-28.
7. McGorry PD. The nature of schizophrenia: signposts to prevention. Aust N Z J Psychiatry 2000;34(Suppl):S14-21.
8. rd ed. Washington DC: American Psychiatric Press, 1999:425-77.
9. Loebel AD, Lieberman JA, Alvir JM, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry 1992;149:1183-8.
10. Beiser M, Erickson D, Fleming JA, Iacono WG. Establishing the onset of psychotic illness. Am J Psychiatry 1993;150:1349-54.
11. Hafner H, Maurer K, Loffler W, Riecher-Rossler A. The influence of age and sex on the onset and early course of schizophrenia. Br J Psychiatry 1993;162:80-6.
12. Jones PB, Bebbington P, Foerster A, Lewis SW, Murray RM, Russell A, et al. Premorbid social underachievement in schizophrenia. Results from the Camberwell Collaborative Psychosis Study. Br J Psychiatry 1993;162:65-71.
13. Yung AR, McGorry PD. The initial prodrome in psychosis: descriptive and qualitative aspects. Aust N Z J Psychiatry 1996;30:587-99.
14. Yung AR, McGorry PD. The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull 1996;22:353-70.
15. Woods SW, Miller TJ, McGlashan TH. The "prodromal" patient: both symptomatic and at risk. CNS Spectrums 2001;6:223-32.
16. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull 1996;22:327-45.
17. Larsen TK, Johannessen JO, Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Br J Psychiatry 1998;172(Suppl 33):45-52.
18. Lieberman JA, Perkins D, Beiger A, Chakos M, Jarskog F, Boteva K, et al. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol Psychiatry 2001;50:884-97.
19. Johnstone EC, Crow TJ, Johnson AL, MacMillan JF. The Northwick Park Study of first episodes of schizophrenia. I. Presentation of the illness and problems relating to admission. Br J Psychiatry 1986;148:115-20.
20. Chong SA, Mythily, Lum A, Chan YH, McGorry P. Determinants of duration of untreated psychosis and the pathway in Singapore. Int J Soc Psychiatry (in press).
21. Drake RJ, Haley CJ, Akhtar S, Lewis SW. Causes and consequences of duration of untreated psychosis in schizophrenia. Br J Psychiatry 2000;177:511-5.
22. Johannessen JO, McGlashan TH, Larsen TK, Homeland M, Joa I, Mardal S, et al. Early detection strategies for untreated first-episode psychosis. Schizophr Res 2001;51:39-46.
23. Helgason L. Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented? Acta Psychiatr Scand 1990;81:231-5.
24. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. Br J Psychiatry 1986;148:120-7.
25. Lieberman JA, Fenton WS. Delayed detection of psychosis: causes, consequences, and effect on public health. Am J Psychiatry 2000;157:1727-30.
26. Larsen TK, Friis S, Haahr U, Joa I, Johannessen JO, Meile I, et al. Early detection and intervention in first-episode schizophrenia: a critical review. Acta Psychiatr Scand 2001;103:323-34.
27. Falloon IR. Early intervention for first episodes of schizophrenia: a preliminary exploration. Psychiatry 1992;55:4-15.
28. rd rev. Washington, DC: American Psychiatric Association, 1987.
29. Yung AR, Phillips LJ, Yuen HP, Francey SM, McFarlane CA, Hallgren M, et al. Psychosis prediction: 12-month follow up of a high-risk (" prodromal") group. Schizophr Res 2003;60:21-32.
30. McGorry PD, Yung A, Phillips L. Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr Res 2001;51:17-29.
31. Yung AR, McGorry PD. Is pre-psychotic intervention realistic in schizophrenia and related disorders? Aust N Z J Psychiatry 1997;31:799-805.
32. Schaffner KF, McGorry PD. Preventing severe mental illnesses - new prospects and ethical challenges. Schizophr Res 2001;51:3-15.
33. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr Bull 1996;22:283-303.
34. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophr Res 2003;61:19-30.
35. Miller TJ, McGlashan TH, Woods SW, Stein K, Driesen N, Corcoran CM, Huffman R, et al. Symptom assessment in schizophrenic prodromal states. Psychiatric Q 1999;70:273-87.
36. Warner R. The prevention of schizophrenia: what interventions are safe and effective? Schizophr Bull 2001;27:551-62.
37. Cornblatt B, Lencz T, Kane JM. Treatment of the schizophrenia prodrome: is it presently ethical? Schizophr Res 2001;51:31-8.
38. Heinimaa, Larsen MA, Tor KB. Psychosis: conceptual and ethical aspects of early diagnosis and intervention. Curr Opin Psychiatry 2002;15:533-41.
39. Lee Cheng, McGlashan TH. Treating schizophrenia earlier in life and the potential of prevention. Curr Psych Therap Rep 2003;35-40.
40. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002;59:921-8.
41. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromal symptomatic for psychosis. I. Study rationale and design. Schizophr Res 2003;61:7-18.
42. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al. Randomized trial of olanzapine vs placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003;54:453-64.
43. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.